Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 878-887

  Antonia, Scott J ^a,b   Mirza, Noweeda ^a   Fricke, Ingo ^a   Chiappori, Alberto ^a,b   Thompson, Patricia ^a   Williams, Nicholas ^a   Bepler, Gerold ^a,b   Simon, George ^a,b   Janssen, William ^a,b   Lee, Ji Hyun ^a   Menander, Kerstin ^c   Chada, Sunil ^c   Gabrilovich, Dmitry I ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Introgen Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; PROTEIN P53; VIRUS ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL FUNCTION; CONTROLLED STUDY; DENDRITIC CELL; FATIGUE; FEMALE; GENE TARGETING; HUMAN; IMMUNE RESPONSE; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYELOID CELLS; PHENOTYPE; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 32944468708     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2013     Document Type: Article

References (43)

1. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3-13.
2. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004;9:25-32.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
4. Bodner SM, Minna J, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
5. D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46.
6. Chada S, Mhashilkar A, Roth JA, Gabrilovich D. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel 2003;6:169-73.
7. Ishida T, Chada S, Stipanov M, et al. Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses. Clin Exp Immunol 1999;117:244-51.
8. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
9. Nikitina EY, Clark JI, van Beynen J, et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7:127-35.
10. van der Burg SH, de Cock K, Menon AG, et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001;31:146-55.
11. van der Burg SH, Menon AG, Redeker A, et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 2002;8:1019-27.
12. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005;54:1072-81.
13. Gabrilovich DI. Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther 2002;4:452-8.
14. Nikitina EY, Chada S, Muro-Cacho C, et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002;9:345-52.
15. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic cell function following transduction with viral vectors; implications for gene therapy. Blood 2005;105:3824-32.
16. Herrera OB, Brett S, Lechler RI. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Vaccine 2002;21:231-42.
17. Humrich J, Jenne L. Viral vectors for dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 2003;276:241-59.
18. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 2004;82:506-16.
19. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003;15:6523-33.
20. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005;54:1153-61.
21. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002;51:293-8.
22. Gabrilovich D. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
23. Davies AM, Evans WK, Mackay JA, Shepherd FA. Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am 2004;18:387-416.
24. Noguchi Y, Chen Y, Old L. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A 1994;91:3171-5.
25. Yanuck M, Carbone DP, Pendleton D, et al. Mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993;53:3257-61.
26. Gabrilovich DI, Cunningham HT, Carbone DP. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J Immunother 1997;19:414-8.
27. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
28. Zwaveling S, Vierboom MP, Ferreira Mota SC, et al. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002;62:6187-93.
29. Parajuli P, Pisarev V, Sublet J, et al. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Cancer Res 2001;61:8227-34.
30. Svane IM, Pedersen AE, Johnsen HE, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004;53:633-41.
31. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002;20:957-65.
32. Miller G, Lahrs S, Shah AB, DeMatteo RP. Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. Cancer Immunol Immunother 2003;52:347-58.
33. Korst RJ, Mahtabifard A, Yamada R, Crystal RG. Effect of adenovirus gene transfer vectors on the immunologic functions of mouse dendritic cells. Mol Ther 2002;5:307-15.
34. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
35. Bronte V, Serafini P, Appoloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001;24:431-46.
36. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997;158:3270-6.
37. Sandier AB. Irinotecan in small-cell lung cancer: the US experience. Oncology 2001;15:11-2.
38. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003;21:1550-5.
39. Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003;9:143-50.
40. Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001;19:119-26.
41. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6.
42. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-26.
43. Lake RA, Robinson BWS. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5:397-405.